Genomics

Dataset Information

0

Correlative studies in Protocol #9204, which studied ipilimumab or nivolumab in hematologic malignancies after transplantation, including studies in collaboration with CIMAC-CIDC

ABSTRACT: Correlative studies in Protocol #9204, which studied ipilimumab or nivolumab in hematologic malignancies after transplantation, including studies in collaboration with CIMAC-CIDC

PROVIDER: PRJNA970487 | ENA |

REPOSITORIES: ENA

Json Xml

Similar Datasets

Genomics Correlative studies in NRG-GY021: Olaparib and tremelimumab in Ovarin cancer (CIMAC-CIDC)
| PRJNA1085796 | ENA
Genomics Correlative studies in Protocol #9204, which studied ipilimumab or nivolumab in hematologic malignancies after transplantation, including studies in collaboration with CIMAC-CIDC
| PRJNA970486 | ENA
Genomics Correlative studies in Protocol NRG-LU004, which studied radiation and immunotherapy in lung cancer, in collaboration with CIMAC-CIDC
| PRJNA1066948 | ENA
Genomics Correlative studies in Protocol E4412, which studied Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma, in collaboration with CIMAC-CIDC
| PRJNA1029315 | ENA
Genomics Correlative studies for Protocol #14-C-0059, which studied anti-GD2-CAR T cells in GD2+ solid tumors, in collaboration with CIMAC-CIDC
| PRJNA1032220 | ENA
Genomics Correlative studies for Protocol #14-C-0059, which studied anti-GD2-CAR T cells in GD2+ solid tumors, in collaboration with CIMAC-CIDC
| PRJNA1032219 | ENA
Genomics E5103 correlative studies
| PRJNA934658 | ENA
Genomics E5103 correlative studies
| PRJNA934659 | ENA
Genomics Correlative study in Protocol S1400I A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB IN STAGE IV SQUAMOUS CELL LUNG CANCER (CIMAC-CIDC)
| PRJNA1014197 | ENA
Genomics Correlative study in Protocol S1400I A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB IN STAGE IV SQUAMOUS CELL LUNG CANCER (CIMAC-CIDC)
| PRJNA1014196 | ENA